Abstract |
Inflammatory bowel diseases (IBD) present a typically relapsing-remitting behavior and are characterized by a disabling and progressive course. Anti- tumor necrosis factor (TNF)-α agents have drastically changed the therapeutic management of IBD. However, a significant proportion of patients does not have a primary response, some patients lose response overtime and/or experience side effects. Recently, anti-adhesion molecules were investigated and showed efficacy with a good safety profile. Vedolizumab was recently approved for both Crohn's disease (CD) and ulcerative colitis (UC) and several other molecules are under evaluation in this field. Anti-adhesion molecules could represent a potential therapeutic option for future therapy in IBD. In this review we report the efficacy and safety of major anti-adhesion drugs in active IBD patients.
|
Authors | Ivana Bravatà, Mariangela Allocca, Gionata Fiorino, Silvio Danese |
Journal | Current opinion in pharmacology
(Curr Opin Pharmacol)
Vol. 25
Pg. 67-71
(Dec 2015)
ISSN: 1471-4973 [Electronic] England |
PMID | 26687159
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2015. Published by Elsevier Ltd. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Cell Adhesion Molecules
- Integrins
|
Topics |
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Cell Adhesion Molecules
(antagonists & inhibitors)
- Humans
- Inflammatory Bowel Diseases
(drug therapy, metabolism)
- Integrins
(antagonists & inhibitors)
- Models, Biological
- Molecular Targeted Therapy
(methods)
|